ncannex Healthcare Limited (Nasdaq: IXHL / ASX: IHL), a pharmaceutical company developing medicinal cannabinoid pharmaceutical products and psychedelic therapies for unmet medical needs, is pleased to announce that it will be featured as a presenting company at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference. The conference is being held virtually on September 26, 2023.
Joel Latham, CEO of Incannex, will provide an overview of the Company’s business during the presentation.
If you are an institutional investor and would like to listen to the Company’s presentation or request a 1×1 meeting, please click on the following link (https://hcwevents.com/neuropsychiatry-conference/) to register for the conference.
Event: H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
1×1 virtual meeting availability: June 26, 2023, 2:00-5:00pm (U.S. eastern time)
Time/Location: Virtual to start on-demand June 26th at 7:00am (U.S. eastern time)
About Incannex Healthcare Limited
Incannex is a clinical stage pharmaceutical development company that is developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications.
U.S. FDA approval and registration, subject to ongoing clinical success, is being pursued for each drug and therapy under development. Each indication under investigation currently has no, or limited, existing registered pharmacotherapy (drug) treatments available to the public and represent major global economic opportunities to Incannex and its shareholders.
Incannex has a strong patent filing strategy in place as it develops its products and therapies in conjunction with its medical and scientific advisory board and partners. The Company holds 19 granted patents and 30 pending patent applications.